Monthly Cost Breakdown: Wegovy vs Mounjaro Dosing Plans
Mounjaro vs Wegovy Dosage: Monthly Cost Planning Essentials
Understanding the Mounjaro vs Wegovy dosage schedules is fundamental to budgeting for your weight management journey. Wegovy follows a structured 16-week dose escalation from 0.25mg to the maintenance dose of 2.4mg, with each month requiring a different strength and price point. Your total investment for the complete Wegovy dose escalation period amounts to £524.96, spread across four distinct monthly costs. Mounjaro follows a similar escalation pattern but with different dose strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg), creating its own monthly cost structure that differs significantly from Wegovy's pricing model.
The financial planning advantage becomes clear when you understand that Wegovy's maintenance dose remains consistent at £209.99 per month once you reach the 2.4mg strength at week 17. This predictability allows for accurate long-term budgeting, with an annual maintenance cost of approximately £2,519.88 for ongoing treatment. EverydayMeds' pricing structure ensures you can plan confidently, knowing that the DOSE25 discount code for returning customers keeps these prices stable for your continued treatment journey.
Wegovy Dosage Schedule: Complete UK Pricing Breakdown
The Wegovy dose escalation follows MHRA-approved guidelines with specific monthly costs at each stage: Month 1 (weeks 1-4) costs £79.99 for the 0.25mg starter dose, Month 2 (weeks 5-8) requires £94.99 for 0.5mg, Month 3 (weeks 9-12) costs £99.99 for 1mg, and Month 4 (weeks 13-16) requires £139.99 for the 1.7mg strength. From Month 5 onwards, you'll maintain the 2.4mg dose at £209.99 monthly, representing your ongoing investment in weight management support. New customers benefit from the FIRST40 discount code applied at checkout, while returning customers use DOSE25 to maintain these competitive prices.
Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99, covering your first three months of treatment in a single order. The Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99, ensuring uninterrupted treatment once you reach the therapeutic dose. These bundles provide supply security and reduce the frequency of ordering, though individual pen purchases offer maximum flexibility for those preferring month-by-month purchasing.
Clinical Evidence Supporting Mounjaro vs Wegovy Dosage Protocols
The STEP clinical trial programme, particularly Wilding et al., NEJM, 2021, demonstrated that Wegovy's dose escalation protocol may support an average weight reduction of approximately 15% at 68 weeks when used alongside a reduced-calorie diet and increased physical activity. The structured dosing approach allows patients to gradually adjust to the medication while minimising potential gastrointestinal side effects during the escalation period.
Mounjaro's SURMOUNT trials showed different outcomes with their dose escalation schedule, though direct comparison between trial results isn't appropriate due to different study designs and patient populations. Both medications require prescription-only access and clinical supervision throughout the dosing journey, ensuring safety and efficacy monitoring as you progress through each dose level.
How Wegovy's GLP-1 Mechanism Supports Dose Escalation
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. The gradual dose escalation allows your body to adapt to increasing levels of GLP-1 receptor activation, potentially reducing food cravings while supporting portion control. This mechanism works on brain appetite centres, helping you feel satisfied with smaller portions as you progress through each dose level. The four-month escalation period provides time for your body to adjust to the medication's effects, with many patients reporting improved appetite control and reduced food cravings as they advance through the dosing schedule. By week 17, the maintenance 2.4mg dose provides consistent therapeutic levels to support ongoing weight management efforts.
Streamlined Ordering Process for Mounjaro vs Wegovy Dosage Needs
EverydayMeds simplifies access to both Mounjaro and Wegovy through our efficient three-step process designed for busy lifestyles. Complete our comprehensive 3-minute online clinical assessment, providing essential medical history and current health information required for prescriber review. Our qualified prescribers review your assessment within three working days (or 24 hours with express service), determining your suitability for either medication and appropriate starting dose. Once approved, your prescription-only medicine ships via next-day cold-chain delivery, maintaining the crucial 2-8°C temperature requirements throughout transit. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and pharmaceutical standards for every order. You'll receive detailed dosing instructions, storage guidance, and ongoing support throughout your treatment journey.
Storage Requirements: Wegovy vs Mounjaro Practical Differences
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, but Wegovy offers superior travel flexibility with up to 6 weeks room temperature storage below 30°C once removed from the fridge, compared to Mounjaro's 21-day limit. The Wegovy FlexTouch pen system provides user-friendly injection experience with clear dose windows and simple operation, while both medications use similar once-weekly injection schedules. Proper storage maintains medication potency throughout your dose escalation journey, whether you're progressing through Wegovy's four-month schedule or Mounjaro's alternative dosing plan. Each pen contains four doses, providing one month's supply regardless of your current dose strength. Understanding these storage differences helps inform your choice between treatments, particularly if you travel frequently or need extended room temperature storage flexibility.
Annual Investment Analysis: Mounjaro vs Wegovy Dosage Costs
Calculating your annual investment for either treatment requires understanding both the initial dose escalation period and ongoing maintenance costs. Wegovy's complete first-year cost includes the £524.96 escalation period plus eight months of 2.4mg maintenance at £209.99 monthly, totaling approximately £2,204.88 for year one. Subsequent years require only the maintenance dose investment of £2,519.88 annually, providing clear long-term financial planning capabilities. This transparent pricing structure allows you to budget confidently for sustained weight management support.
The predictable maintenance cost structure means you can plan financially for long-term treatment success, understanding exactly what your monthly commitment will be once you reach therapeutic dosing. EverydayMeds' DOSE25 returning customer code ensures these prices remain accessible throughout your treatment journey, providing cost stability alongside clinical support for achieving and maintaining your weight management goals.
Secure Your Mounjaro vs Wegovy Treatment Today
Both Wegovy and Mounjaro are available from EverydayMeds, with your prescriber able to help determine which treatment and dosing schedule best suits your individual needs and budget. New customers can start their Wegovy journey using code FIRST40 at checkout, while returning customers benefit from DOSE25 for continued savings on their monthly supply. Our clinical team provides ongoing support throughout your dose escalation period, ensuring you understand each step of your treatment journey and associated costs. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and discover which treatment option aligns with your weight management goals and monthly budget. With transparent pricing, reliable supply, and expert clinical support, EverydayMeds makes accessing prescription-only weight management treatments straightforward and affordable.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
